K

The two-particle momentum correlation function of a K^{-}p pair from high-energy nuclear collisions is evaluated in the K[over ¯]N-πΣ-πΛ coupled-channel framework. The effects of all coupled channels together with the Coulomb potential and the threshold energy difference between K^{-}p and K[over ¯]^{0}n are treated completely for the first time. Realistic potentials based on the chiral SU(3) dynamics are used which fit the available scattering data. The recently measured correlation function is found to be well reproduced by allowing variations of the source size and the relative weight of the source function of πΣ with respect to that of K[over ¯]N. The predicted K^{-}p correlation function from larger systems indicates that the investigation of its source size dependence is useful in providing further constraints in the study of the K[over ¯]N interaction.

Identifying multiquark hadrons from heavy ion collisions.

Identifying hadronic molecular states and/or hadrons with multiquark components either with or without exotic quantum numbers is a long-standing challenge in hadronic physics. We suggest that studying the production of these hadrons in relativistic heavy ion collisions offers a promising resolution to this problem as yields of exotic hadrons are expected to be strongly affected by their structures. Using the coalescence model for hadron production, we find that, compared to the case of a nonexotic hadron with normal quark numbers, the yield of an exotic hadron is typically an order of magnitude smaller when it is a compact multiquark state and a factor of 2 or more larger when it is a loosely bound hadronic molecule. We further find that some of the newly proposed heavy exotic states could be produced and realistically measured in these experiments.

Establishment of acute kidney injury mouse model by 0.75% adenine ingestion.

BACKGROUND: Acute kidney injury (AKI) has a profound impact on the morbidity and mortality of patients. Tubular obstruction is an important mechanism of AKI development because many molecules will cause tubular obstruction, leading to AKI; however, few AKI animal models by tubular obstruction have been established. The aim of this study was to establish AKI model mice due to tubular obstruction. METHOD: C57BL/6 male mice, aged 10 weeks, 20-30 g body weight, were ingested 0.75% adenine compound food. The mice were sacrificed from day 1 to 5 for blood, urine, and histological analysis. RESULTS: All mice (50/50 mice) developed AKI and had died by day 6 of uremia after ingesting 0.75% adenine. Histological examination of the kidneys of AKI mice showed that dilatation of the tubular lumen in the medullary papilla resulted from the occupation by adenine casts followed by atrophy, scattering, and flattening of the epithelial cells of tubules. The urine neutrophil gelatinase-associated lipocalin (NGAL) level significantly increased in AKI mice on day 1 after ingesting 0.75% adenine. CONCLUSION: We established a very simple and reproducible AKI mouse model due to tubular obstruction by ingesting 0.75% adenine.

Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.

The purpose of this study was to evaluate the retention and discontinuation reasons of seven biological disease-modifying antirheumatic drugs (bDMARDs) in a real-world setting of patients with rheumatoid arthritis (RA). 1,037 treatment courses with bDMARDs from 2009 to 2016 [female, 81.8%; baseline age, 59.6 y; disease duration 7.8 y; rheumatoid factor positivity 81.5%; Disease Activity Score in 28 joints using erythrocyte sedimentation rate (DAS28-ESR), 4.4; concomitant prednisolone 43.5% and methotrexate 68.6%; Bio-naïve, 57.1%; abatacept (ABT), 21.3%; tocilizumab (TCZ), 20.7%; golimumab (GLM), 16.9%; etanercept (ETN), 13.6%; adalimumab (ADA), 11.1%; infliximab (IFX), 8.5%; certolizumab pegol (CZP), 7.9%] were included in this multi-center, retrospective study. Drug retention and discontinuation reasons at 36 months were estimated using the Kaplan-Meier method and adjusted by potent confounders using Cox proportional hazards modeling. As a result, 455 treatment courses (43.9%) were stopped, with 217 (20.9%) stopping due to inefficacy, 113 (10.9%) due to non-toxic reasons, 86 (8.3%) due to toxic adverse events, and 39 (3.8%) due to remission. Drug retention rates in the adjusted model were as follows: total retention (ABT, 60.7%; ADA, 32.7%; CZP, 43.3%; ETN, 51.9%; GLM, 45.4%; IFX, 31.1%; and TCZ, 59.2%; P < 0.001); inefficacy (ABT, 81.4%; ADA, 65.7%; CZP, 60.7%; ETN, 71.3%; GLM, 68.5%; IFX, 65.0%; and TCZ, 81.4%; P = 0.015), toxic adverse events (ABT, 89.8%; ADA, 80.5%; CZP, 83.9%; ETN, 89.2%; GLM, 85.5%; IFX, 75.6%; and TCZ, 77.2%; P = 0.50), and remission (ABT, 95.5%; ADA, 88.1%; CZP, 91.1%; ETN, 97.5%; GLM, 94.7%; IFX, 86.4%; and TCZ, 98.4%; P < 0.001). In the treatment of RA, ABT and TCZ showed higher overall retention, and TCZ showed lower inefficacy compared to IFX, while IFX showed higher discontinuation due to remission compared to ABT, ETN, GLM, and TCZ in adjusted modeling.

Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.

BACKGROUND: Clinical remission can be maintained after the discontinuation of biological disease-modifying antirheumatic drugs (bDMARDs) in some patients with rheumatoid arthritis (RA) (bDMARD-free remission (BFR)). It is unknown which bDMARD is advantageous for achieving BFR or under which conditions BFR can be considered. This study aimed to determine the factors associated with BFR achievement in clinical practice. METHODS: Patients with RA were enrolled from a Japanese multicenter observational registry. Patients with RA who achieved clinical remission (Disease Activity Score 28-C-reactive protein < 2.3) at the time of bDMARD discontinuation were included. Serial disease activities and treatment changes were followed up. BFR was considered to have failed if the disease activity exceeded the remission cutoff value or if bDMARDs were restarted. RESULTS: Overall, 181 RA patients were included. BFR was maintained in 21.5% of patients at 1 year after bDMARD discontinuation. BFR was more successfully achieved after discontinuation of anti-tumor necrosis factor (TNF) monoclonal antibodies (TNFi(mAb)) (infliximab, adalimumab, and golimumab), followed by CTLA4-Ig (abatacept), soluble TNF receptor or Fab fragments against TNF fused with polyethylene glycol (etanercept and certolizumab), and anti-interleukin-6 receptor Ab (tocilizumab). After multivariate analysis, sustained remission (> 6 months), Boolean remission, no glucocorticoid use at the time of bDMARD discontinuation, and use of TNFi(mAb) or CTLA4-Ig remained as independent factors associated with BFR. CONCLUSIONS: BFR can be achieved in some patients with RA after bDMARD discontinuation in clinical practice. Use of TNFi(mAb) or CTLA4-Ig, sustained remission, Boolean remission, and no glucocorticoid use at the time of bDMARD discontinuation are advantageous for achieving BFR.

Computational design of solar reflection and far-infrared transmission films for a variable emittance device.

A smart radiation device (SRD) that is a variable emittance radiator has been studied as a method of thermal control for spacecraft. The SRD consists of manganese oxide with a perovskite-type structure, and the total hemispherical emittance of the SRD changes considerably depending on temperature. Here we propose an optimal method of designing multilayer films for the SRD by using agenetic algorithm. The multilayer films reflect solar radiation and transmit far-infrared radiation to maintain variation of the infrared optical properties of the SRD.